← Back
$ARTV All transactions

Artiva Biotherapeutics, Inc.

F 10b5-1 Plan

$ Value

$12K

Shares

4,472

Price

$3

Filed

Aug 18

Insider

Name

Aslan Fred

Title

President and CEO

CIK

0001909362

Roles

Director Officer

Transaction Details

Transaction Date

2025-08-15

Code

F

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

382,221

Footnotes

Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards. | Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 23, 2024, to satisfy income tax obligations associated with the vesting of restricted stock unit awards. | The weighted average sale price for the transaction reported was $2.7286, and the range of prices were between $2.60 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Filing Info

Accession No.

0001415889-25-022224

Form Type

4

Issuer CIK

0001817241

Aslan Fred's History

Date Ticker Type Value
2026-02-15 ARTV A $0
2026-02-15 ARTV F $58K
2025-12-15 ARTV $19K
2025-12-12 ARTV A $0
2025-12-12 ARTV D
2025-12-12 ARTV D
2025-12-12 ARTV D
2025-12-12 ARTV D
2025-12-12 ARTV D
2025-12-12 ARTV D

Other Insiders at ARTV (90d)

Insider Bought Sold Last
Bush Jennifer
COO, CLO, Secy, Compliance Off
2026-02-15
Horan Christopher
Chief Tech Operations Officer
2026-02-15
Sorg Elaine K. 2026-02-18
Aslan Fred
President and CEO
2026-02-15
Raymon Heather
SVP, Research and Development
2026-02-15
Banerjee Subhashis
Chief Medical Officer
2026-02-15